Tiziana Life Sciences Doses Patients in SPMS Trial at Johns Hopkins
Ticker: TLSA · Form: 6-K · Filed: Apr 2, 2025 · CIK: 1723069
| Field | Detail |
|---|---|
| Company | Tiziana Life Sciences Ltd (TLSA) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, multiple-sclerosis
TL;DR
Tiziana Life Sciences starts dosing SPMS patients at Johns Hopkins for foralumab trial.
AI Summary
Tiziana Life Sciences Ltd. announced on April 2, 2025, that dosing has begun at Johns Hopkins University (JHU) Autoimmunity Center of Excellence for its Phase 2 trial. This trial is evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (SPMS). JHU is the third clinical site to initiate patient dosing in this study.
Why It Matters
The initiation of dosing at a major research institution like Johns Hopkins is a significant step forward in evaluating foralumab's potential to treat a debilitating form of multiple sclerosis.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- Tiziana Life Sciences Ltd (company) — Registrant
- Johns Hopkins University (company) — Clinical Trial Site
- foralumab (drug) — Investigational Treatment
- Secondary Progressive Multiple Sclerosis (disease) — Target Condition
- April 2, 2025 (date) — Announcement Date
FAQ
What is the specific indication being studied for intranasal foralumab?
The Phase 2 trial is evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (SPMS).
Which university is now dosing patients in the Phase 2 trial?
Johns Hopkins University (JHU) Autoimmunity Center of Excellence is now dosing patients.
How many clinical sites have commenced dosing in this trial?
Johns Hopkins University is the third clinical site to commence patient dosing.
What is the form type of this SEC filing?
This is a Form 6-K, a Report of Foreign Private Issuer.
What is the filing date of this report?
The filing date is April 2, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 2, 2025 regarding Tiziana Life Sciences Ltd (TLSA).